When, if ever, would you consider deep venous thrombosis prophylaxis for patients with advanced epithelial ovarian cancer undergoing neoadjuvant chemotherapy?  

In your practice, what is the proportion of patients receiving neoadjuvant chemotherapy who are diagnosed with VTE? Does this differ from patients receiving adjuvant chemotherapy or chemotherapy for recurrent disease? 

Answer from: at Academic Institution

Answer from: at Community Practice